Benign Prostatic Hypertrophy (BPH) is the most
|
|
- Christiana Robbins
- 5 years ago
- Views:
Transcription
1 Medical treatment of benign prostatic hypertrophy There is little doubt that medical therapy has transformed the treatment of benign prostatic hypertrophy (BPH). The medical treatment of BPH continues to be based on two main classes of drugs, alpha adrenergic blockers and 5-alpha reductase inhibitors. Dr Yeung Ng Specialist Registrar, Department of Urology, Queen Margaret Hospital, Dunfermline, Scotland Mr David Gordon Brown Consultant Urological Surgeon,Department of Urology, Queen Margaret Hospital, Dunfermline, Scotland Benign Prostatic Hypertrophy (BPH) is the most common reason for men over the age of 50 years to consult a urologist. Strictly speaking, BPH is a histological diagnosis defined by the presence of stromoglandular hyperplasia in prostate tissue. Autopsy data has shown that there is a sigmoid distribution of BPH with age. 1 There is an 8% prevalence in the years age group, rising to 50% in the years group and 88% in those aged over 80 years. Prostate volume also shows a linear increase with age. BPH is intimately linked to the clinical symptoms collectively known as lower urinary tract symptoms (LUTS), in particular reduced urinary flow. Clinically reported LUTS has been reported in 17% of men aged 50 59, 27% aged and in 35% of men over the age of 70 years. 2 Diagnosis LUTS are a collective group of symptoms characterised by poor flow, frequency, nocturia, urgency, post micturition dribbling and incomplete emptying. The IPSS/AUA questionnaires are universally used scoring systems to calculate the patients perceived severity of symptoms. 3 There are six symptom domains scored from 0 5 plus a quality of life score. A score of less than 8 signifies mild symptoms, 8 19 moderate symptoms and severe symptoms. The most commonly used objective measurement of outflow obstruction is uroflowmetry. The patient is asked to void into a flow machine that plots a trace of urinary flow rate against time. A maximum flow rate of less than 10ml/s signifies a high probability of obstruction whilst a flow rate of greater than 15ml/s generally suggests obstruction is unlikely although results can be confounded by weak detrusor muscle contraction. 4 The shape of the graph and voiding time are important as prolonged voiding times and a flattening of the graph may indicate obstruction. Generally uroflowmetry is undertaken in conjunction with a post void scan of bladder residual volume to assess incomplete emptying. Clinical assessment of prostatic volume by digital rectal examination is necessary. It is difficult for the non specialist to accurately assess prostate size, but a non enlarged gland should be less than 25cc or classically described as the size of a walnut. A benign gland is smooth, symmetrical, regular and with a median sulcus. Any variation from this may represent a prostate cancer and should be referred for a urological opinion. Other baseline investigations are urinalysis and culture and baseline serum creatinine. The use of routine prostatespecific antigen (PSA) testing remains controversial with relation to screening for prostate cancer and is beyond the scope of this article. With regard to BPH and LUTS, a PSA of greater than 1. 4 has been associated with symptom progression. 5 It is common practice to check PSA as a baseline investigation. BPH has a number of clinical complications. Urinary retention must be considered to be the disease endpoint. It is the most recognised but not most common sequelae of BPH and occurs with an incidence of between 0. 6 and 1. 8 times/100 patient years. 5,6,7 Poor urinary flow (<12ml/s), larger prostate volume (>30ml), age and IPSS score are all risk factors. A PSA of >1. 4 also increases risk of retention. Bladder stones may occur with an incidence of up to 3. 4% or eight times greater than non bladder outflow obstruction patients 8 due to urinary stasis. Frank haematuria is self reported in 2. 5% of BPH patients. 9 Urinary tract infection 14
2 is actually comparatively rare (0. 1 times/100 patient years) as is post renal failure. Bladder decompensation can occur and this results in a chronic painless urinary retention with a large residual bladder volume of greater than 750ml. Placebo BPH and LUTS is unusual in that both natural history and the placebo arms of treatment studies have shown that around 40% of patients with LUTS will report improvement of symptoms without treatment. 4,10 However, this effect appears to be temporary and long term studies show a reversal of placebo effect after one year and progression of symptoms after this time. Pharmaceutical treatment The medical treatment of BPH continues to be based on two main classes of drugs, alpha adrenergic blockers and 5-alpha reductase inhibitors. Alpha adrenergic blockers Human prostate contains smooth muscle that contracts in the presence of alpha adrenergic agonist such as norepinephrine. The majority of smooth muscle is located in a ring around the base of the bladder and failure of this to relax with voiding may be the principle factor in the reduction in urinary flow rate. Alpha 1 adrenergic receptors mediate this contraction and indeed the human prostate contains 98% of these receptors in the body. Alpha-1 a subtypes predominate in the prostate and urethra, d subtypes in the bladder and sacral cord and b subtypes in vascular smooth muscles. The a subtype increases in vascular muscle in proportion with ageing. 11 There are numerous alpha blockers on the market though once daily preparations now prevail. They remain the most commonly prescribed medication for BPH. Although many placebo controlled studies exist, most are six months or less in duration and there are very few head to head studies between different drugs. Tamsulosin MR/XL is the most potent alpha blocker and has some selectivity for alpha 1 a and d receptor subtypes as opposed to b. However, this does not appear to translate to any clinical advantage. A Cochrane review looking at 4,122 patients in 14 studies (six placebo controlled) found that tamsulosin treatment resulted in a mean reduction in IPSS score of 2. 1 versus placebo, improved quality of life and a mean improvement in peak flow of 1.05ml/s over placebo. 12 Only two small head to head studies have been conducted versus terazosin and alfuzosin and showed similar efficacy. Alfuzosin XL shows similar improvements in flow and symptoms to other alpha blockers with extension studies up to 30 months. 13 It is notable in that it is the only drug that has been shown to result in increased success of trial removal of catheter (TROC) post urinary retention. A placebo controlled study showed a 55% versus 29% significant successful TROC rate after 24 hours of catheterisation with two days of alfuzosin treatment. 14 A six month extension trial did show a lower percentage of patients proceeding to TURP (17% versus 24%). Doxazosin is a long acting alpha blocker with a half life of over 22 hours. However, it exhibits blood pressure lowering properties and needs to be titrated up from 2mg to 8mg. 15 These properties have limited its use. Its symptom relieving efficacy has been shown to be maintained in 42 month extension studies. 16 In addition the MTOPS study 7 has shown that it works synergistically with finasteride in reducing symptom progression and this has lead to its more widespread use. In summary, there appears to be little to choose between the various alpha blockers and they are probably of similar efficacy. It may be worth noting that only alfuzosin XL has been shown to increase the success of TROC after retention and to date, only doxazosin has been shown to have a synergistic effect with finasteride in combination therapy. Alpha blocker therapy is associated with dropout rates of 10 15%. The most commonly reported side effect is orthostatic hypotension, especially after the first dose and it is generally recommended that the first dose is taken at bedtime. Gastrointestinal disturbance is reported, as are hypersensitivity reactions and retrograde ejaculation. Severe hepatic and renal impairment are contraindications to taking this medication. 5-alpha reductase inhibitors 5-alpha reductase inhibitors (5 ARI) block the conversion of testosterone to dihydrotestosterone in the prostate by inhibition of the responsible enzyme. The latter is the main androgen in the prostate and has a potency times greater than testosterone. Androgens are required for normal embryonic development of the prostate and their withdrawal in adults results in a reduction in prostatic volume due to regression of epithelial elements. 17 Finasteride was the first 5ARI and is the most studied. Studies have shown that this is effective in reducing prostatic volume by up to 18% at one year, rising to GM2 Midlife and Beyond 2010 June 15
3 32% after four years of treatment. 5 It reduces both IPSS scores by 1 2 points and improves peak flow by 1 2ml/s. However, in contrast to alpha blockers, finasteride takes six months to produce a significant clinical effect. Its effect on the incidence of acute urinary retention is shown in a number of studies. Both the PLESS 5 and PROWESS 18 studies, which studied finasteride 5mg versus placebo, showed 57% relative reductions in urinary retention in the study group over placebo at four and two years points respectively. However, this reduction in retention rates is volume dependent. Large scale studies where the mean prostate volume is less than 40mg have shown no significant reduction in urinary retention rates with finasteride over placebo 10,19 whilst subset analyses of prostate volumes of greater than 50ml show greater relative reductions in urinary retention rates with 5ARI treatment. It should be noted that urinary retention is a comparatively rare event and that an absolute reduction in retention incidence from 7 to 3% in PLESS translates to the need to treat 25 men for four years to prevent one episode of retention. Finasteride is the medical treatment of choice in treating frank haematuria secondary to BPH. Frank haematuria secondary to BPH resolves in 91% of patients treated with at least six months of finasteride. 20 Dutasteride is a new 5ARI that unlike finasteride inhibits both isoforms of 5-alpha reductase and has a greater impact on serum DHT levels. Dutasteride reduces the IPSS score by 4. 5 points and improves flow by 2. 2ml/s at 24 months and appears to act quicker than finasteride with significant symptom reduction versus placebo by four months. 21,22,23 More recent data has pointed to a continued reduction in symptom scores with longer durations of treatment. Prostate volume reduction is 13. 8% by three months, 23. 6% at one year and 27. 3% by four years. The effect on urinary retention and progression was studied in a four year study of 4,844 men (COMBAT) 24 and results found that combination therapy of dutasteride and tamsulosin was significantly superior to both monotherapies at reducing the relative risk of BPH clinical progression. Side effects of 5ARIs are retrograde ejaculation, impotence and decreased libido in up to 5% of patients, hypersensitivity reactions especially rash and breast tenderness. Both ARIs lower PSA by around 50% with large interpatient variability so baseline PSA should be checked prior to starting therapy. Phytotherapy The use of natural plant products for the treatment of BPH has gained some interest particularly amongst patients. The most well known are Saw Palmetto Berry (Seronea Repens), South African Star Grass (Hypoxis Rooperi) and African Plum (Pygeum africanum). The mechanism of action of these plants is poorly understood but may be due to alteration of growth factor induced prostatic hypertrophy, especially EGF and bfgf. The literature supporting the use of these extracts is comparatively weak and there are few placebo controlled trials. A small meta-analysis on Saw Palmetto 25 has been completed that showed modest improvements in urinary flow and IPSS scores together with a small reduction in nocturia. A double blind placebo controlled trial using Hypoxi Rooperi showed quite significant improvements in flow, IPSS and quality of life but these results have not been replicated in over a decade. 26 No studies have ever looked at progression rates or long-term safety and so phytotherapy cannot generally 16
4 be recommended as an alternative to conventional medical therapy. Combination therapy The interest in the concomitant use of 5ARIs and alpha adrenergic blockers has been prompted by the MTOPS study of 3047 men over the age of 50 years with moderate to severe LUTS. 7 Doxazosin 8mg, finasteride 5mg, combination, or placebo groups were followed up after four years of treatment with primary endpoints centring around progression of symptoms (rise in IPSS of 4) or complications including retention, UTI, renal function deterioration and incontinence. A deterioration in IPSS scores (ie. symptoms) was the most common event (14%) whilst urinary retention occurred in 2% and BPH surgery was carried out in 5% of patients. The reduction in risk of progression (in any form) was 39% for doxazosin alone, 34% for finasteride and 67% for combination treatment compared to placebo. However, when only urinary retention was taken into consideration, doxazosin was not significantly beneficial over placebo and only finasteride or combination groups showed relative reductions of 69 and 64% respectively versus placebo. It should be pointed out that several previous studies on combination therapy (Veterans, PREDICT and ALFIN) 10,13,19 did not show benefit of finasteride although mean prostate volumes were all less than 40cc in these studies. A new fixed-dose combination therapy (dutasteride 0. 5mg/tamsulosin hydrochloride 0. 4mg) is the first single capsule, fixed-dose combination therapy to be approved in Europe for the treatment of moderate-to-severe symptoms of BPH. The impact of medical therapy There is little doubt that medical therapy has transformed the treatment of BPH. Prior to the 1980s, open prostatectomy was the only real option for the treatment of BPH. Despite this procedure being superseded by transurethral prostatectomy, the prostatectomy rate has fallen by around 50% in both the USA and the UK. 27 Over the same period the incidence of reported LUTS has increased by around 40%. Medical therapy is increasingly used particularly in primary care, where the UK use of these drugs increased five fold from 1992 to Indications for referral to a urologist and treatment guidelines Medical therapy can be started by a non urologist for symptomatic patients. This is usually in the form of an alpha blocker given their rapid onset of action. Referral to a urologist is warranted if symptoms remain troublesome despite medical therapy. Obviously, urinary retention, obstructive renal failure and frank haematuria warrant urgent referral. Other indications include persistent dipstick haematuria recurrent urinary infection and bladder stones. Guidelines on referral have been published by the British Association of Urological Surgeons 28 (www. eguidelines.co.uk) and the European Association of Urology 29 has guidelines on investigation and treatment ( Conclusion Men presenting to their physician complaining of LUTS require a careful history and symptom assessment. The clinician should always perform a digital rectal examination to assess the size and nature of the prostate gland as malignancy may present in the same way as BPH. Assessment of the flow rate and residual scan are often available through nurse-led clinics. The assessment of these can influence the treatment given and determine whether the involvement of the local urology department is necessary. Larger prostates respond better to 5ARI drugs though the mainstay of treatment is the use of alpha blockers. Alpha adrenergic blockers are rapidly effective in terms of symptom relief and improve the success rates of spontaneous passage of urine post catheter removal. 5ARIs reduce prostatic volume and improve symptoms after six months. Combination therapy has benefits over monotherapy with either of the above classes of drug and is worth considering particularly in symptomatic patients who are already on one drug. We have no conflict of interest References 1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132(3): Logie J, Clifford GM, Farmer RD. Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int 2005; 95(4): Barry MJ, Fowler FJ Jr, O Leary MP, et al. The American Urological Association symptom index for benign 18
5 prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148(5): Reynard JM, Yang Q, Donovan JL, et al. The ICS- BPH Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998; 82(5): Roehrborn CG, Bruskewitz R, Nickel GC, et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. Eur Urol 2000; 37(5): Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53(3): McConell JD, Roehrburn CG, Bautista OM, et al. The MTOPS research group. The long term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prosatic hyperplasia. N Engl J Med 2003; 349: Grosse H. Frequency, localization and associated disorders in urinary calculi. Analysis of 1671 autopsies in urolithiasis. Z Urol Nephrol 1990; 83(9): Hunter DJ, Berra-Unamuno A, Martin-Gordo A. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older. J Urol 1996; 155(6): Lepor H, Williford WO, Barry MJ, et al.the impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 1998; 160(4): Schwinn DA. The role of a1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU International 2001; 88(2): Wilt T, MacDonald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2002, Issue Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998; 34(3): Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebocontrolled trial. BJU Int 1999; 84(6): Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154(1): Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol 1997; 157(2): McConnell JD. Prostatic growth: new insights into hormonal regulation Br J Urol 1995; 76(1): Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a doubleblind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998; 51(5): Kirby RS, Roehrborn C, Boyle P, Prospective European Doxazosin and Combination Therapy Study InvestigatorsEfficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61(1): Sieber PR, Rommel FM, Huffnagle HW, et al. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. J Urol 1998; 159(4): Debruyne F, Barkin J, van Erps P, et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004; 46(4): Roehrborn CG, Boyle P, Nickel JC, et al Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60(3): Roehrborn CG, Lukkarinen O, Mark S, et al. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005; 96(4): Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57(1): Wilt T, Ishani A, MacDonald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2002, Issue Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 1995 ; 345(8964): Lu-Yao GL, Barry MJ, Chang CH, et al. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 1994; 44(5): Speakman MJ, Kirby RS, Joyce A, et al. The British Association of Urological Surgeons. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004; 93(7): EAU Guidelines on Benign Prostate Hypertrophy: GM2 Midlife and Beyond 2010 June 19
The Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationCombination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationOffice Management of Benign Prostatic Enlargement
Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,
More informationRecommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Recommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The development of safe and effective drugs
More informationDuring the past decade, numerous
Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease.
More informationα-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.248 Voiding Dysfunction α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia;
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationBenign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran
Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark Studies Vijayan Manogran MTOPS & CombAT PLESS SMART ALTESS ALF-ONE VA PREDICT EPICS Landmark Studies MTOPS Medical Therapy of Prostatic Symptoms
More informationTherapeutic Strategies for Managing BPH Progression
european urology supplements 5 (2006) 997 1003 available at www.sciencedirect.com journal homepage: www.europeanurology.com Therapeutic Strategies for Managing BPH Progression John M. Fitzpatrick a, *,
More informationCurrent drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The range of drug treatments for BPH, alone
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, of prostate, holmium laser, 485 495 African prune tree (Pygeum africanum), 454 455 Alfuzosin, 445 446 Alpha-adrenergic agonists,
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationHow Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?
available at www.sciencedirect.com journal homepage: www.europeanurology.com How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?
More informationLONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
0022-5347/03/1702-0498/0 Vol. 170, 498 502, August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000076140.68657.fd LONG-TERM SAFETY
More informationWill Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?
Urol Sci 2011;22(1):14 18 MINI REVIEW Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Thomas I.S. Hwang 1,2,3 * 1 Shin Kong WHS Hospital, Taipei,
More informationManagement of LUTS. Simon Woodhams February 2012
Management of LUTS Simon Woodhams February 2012 The management of lower urinary tract symptoms (LUTS) in men Implementing NICE guidance May 2010 NICE clinical guideline 97 Background Lower urinary tract
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy or benign prostatic obstruction, is a condition in
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationPROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment
PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA A Minimally Invasive Innovative Treatment What is the prostate? The prostate is an accessory organ of the male reproductive system.
More informationBenign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy
Benign Prostatic Hyperplasia Management of Benign Prostatic Hyperplasia Goals of Therapy Improve or abolish lower urinary tract symptoms (LUTS) Prevent or delay clinical progression of benign prostatic
More informationMEDICAL THERAPY. Endocrine Approaches. Página 1 de 5.
Página 1 de 5 MEDICAL THERAPY Part of "32 - BENIGN PROSTATIC HYPERPLASIA" Use of pharmacologically defined and a variety of so-called alternative medications to attempt to improve BPH voiding dysfunction
More informationMedical Therapy for Benign Prostatic Hyperplasia Present and Future Impact
REPORTS Medical Therapy for Benign Prostatic Hyperplasia Present and Future Impact Muta M. Issa, MD, MBA; Timothy S. Regan, BPharm, RPh, CPh Abstract The purpose of this manuscript is to provide clinicians,
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationAlpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride
European Urology European Urology 44 (2003) 461 466 Alpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride J.
More informationPRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationHyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.681 Voiding Dysfunction Effect of Shifting from Combination Therapy to Monotherapy of α-blockers or 5α-Reductase Inhibitors on Prostate Volume
More informationDIAGNOSED WITH BENIGN PROSTATIC HYPERPLASIA
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 74 No. 4 pp. 1247ñ1253, 2017 ISSN 0001-6837 Polish Pharmaceutical Society PHARMACOLOGY CLINICAL EVALUATION OF α-1-adrenolytics IN PATIENTS DIAGNOSED WITH
More informationGuideline for the primary care management of male lower urinary tract symptoms
review Article GUIDELINES FOR LUTS M.J. SPEAKMAN et al. As my Comment in the first section of the journal suggested, the MTOPS results have offered the possibility to general practitioners of reducing
More informationProstate Health PHARMACIST VIEW
Prostate Health PHARMACIST VIEW Prostate Definition Prostate is a gland made of fibromuscular tissue. It is about 4 cm and surrounds the neck of the bladder and the urethra. It produces seminal fluid.
More informationMODULE 3: BENIGN PROSTATIC HYPERTROPHY
MODULE 3: BENIGN PROSTATIC HYPERTROPHY KEYWORDS: Prostatic hypertrophy, prostatic hyperplasia, PSA, voiding dysfunction, lower urinary tract symptoms (LUTS) At the end of this clerkship, the medical student
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationAbstract. Key words Trial without catheter, Acute urinary retention, Benign prostatic hyperplasia, Introduction
The role of sustained-released alfuzosin in the treatment of acute urinary retention Mohamed Fawzi Ahmed. Department of Surgery, Ninevah College of Medicine, University of Mosul. Abstract To see whether
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationISSN: (Print) (Online) Journal homepage:
Archives of Andrology Journal of Reproductive Systems ISSN: 0148-5016 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/iaan19 CHANGE IN INTERNATIONAL PROSTATE SYMPTOM SCORE AFTER TRANSURETHRAL
More informationProstate Disease. Chad Baxter, MD
Prostate Disease Chad Baxter, MD Managing BPH and LUTS Chad Baxter, MD Department of Urology cbaxter@mednet.ucla.edu 33 nd Annual UCLA Intensive Course in Geriatric Medicine & Board Review Prevalence of
More informationCan men with prostates sized 80 ml or larger be managed conservatively?
Original Article - Lower Urinary Tract Dysfunction Investig Clin Urol 2017;58:359-364. pissn 2466-0493 eissn 2466-054X Can men with prostates sized 80 ml or larger be managed conservatively? Alvin Lee,
More informationLiterature Scan: Drugs for BPH
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationProstate Gland Volume and Its Relationship to Complications of Benign Prostatic Enlargement
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 6 Ver. II (Jun. 2015), PP 33-37 www.iosrjournals.org Prostate Gland Volume and Its Relationship
More informationNOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate
NOTE: This policy is not effective until April 1, 2019. Medical Policy Manual Surgery, Policy No. 210 Transurethral Water Vapor Thermal Therapy of the Prostate Next Review: December 2019 Last Review: December
More informationMale Lower Urinary Tract Symptoms: Management in primary care and beyond. Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon
Male Lower Urinary Tract Symptoms: Management in primary care and beyond Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon 1 LUTS Very common: 1/3 men over age of 50 have moderate to severe LUTS
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationREPORTS. Clinical and Economic Outcomes in Patients Treated for Enlarged Prostate
Clinical and Economic Outcomes in Patients Treated for Enlarged Prostate Michael James Naslund, MD, MBA; Muta M. Issa, MD, MBA; Amy L. Grogg, PharmD; Michael T. Eaddy, PharmD, PhD; and Libby Black, PharmD
More informationRole of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia
[Medicine Update (2003): 11(2), 55-58] Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia Arora, R.P., CMO, Rajiba L.
More informationOriginal Article Japanese Urological Association. International Journal of Urology (2006) 13,
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd2006130014051409Original ArticleTamsulosin vs doxazosin in BPH D Rahardjo
More informationDOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of benign prostatic hyperplasia treatment of benign prostatic pdf treatment of benign prostatic
More informationManaging lower urinary tract symptoms in men
Managing lower urinary tract symptoms in men MacKenzie KR, Aning JJ. Managing lower urinary tract symptoms in men. Practitioner 6; 6(79):-6 Mr Kenneth R MacKenzie MBChB MRCS (Ed) Core Trainee in Urology
More informationAN OVERVIEW OF THE MANAGEMENT OF MALE LOWER URINARY TRACT SYMPTOMS AND BENIGN PROSTATIC OBSTRUCTION
AN OVERVIEW OF THE MANAGEMENT OF MALE LOWER URINARY TRACT SYMPTOMS AND BENIGN PROSTATIC OBSTRUCTION *Richard Christian Rowan Nayar, Hashim Hashim Continence and Urodynamics Unit, Bristol Urological Institute,
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationBenign Prostatic Hyperplasia and Enlarged Prostate Guidelines: How They Can Be Useful to Primary Care
Volume 1, Number 1 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and Prostate Health,
More informationEvaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia
469245JMHXXX10.1177/1557988312469245A merican Journal of Men s HealthKruep et al. Article Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia American Journal
More informationThe Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial
european urology 54 (2008) 1379 1384 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia The Relationship between Prostate Inflammation and Lower Urinary
More informationTransurethral resection of the prostate (TURP)
This information tells you about an operation on the prostate called a transurethral resection of the prostate (TURP). It explains how the operation is done, how it can help, what the risks are and what
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationBenign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH) Definition Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH), prostate gland enlargement can cause bothersome
More informationWhat is Benign Prostatic Hyperplasia (BPH)?
What is Benign Prostatic Hyperplasia (BPH)? Benign prostatic hyperplasia (BPH) is an enlarged prostate. The prostate goes through two main growth periods as a man ages. The first occurs early in puberty,
More informationAs man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder LUTS 2. Prevalence of BPH LUTS 5
BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG Beaconsfield Medical Practice, Brighton As man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder
More informationOverview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014
Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia Iain McAuley September 15, 2014 Overview Review of the most recent guidelines for ED and BPH ED Guidelines CUA 2006 AUA 2011
More informationThe Hallmarks of BPH Progression and Risk Factors
European Urology Supplements European Urology Supplements 2 (23) 2 7 The Hallmarks of BPH Progression and Risk Factors M. Emberton * Institute of Urology and Nephrology, University College London, 48 Riding
More informationCHAPTER 6. M.D. Eckhardt, G.E.P.M. van Venrooij, T.A. Boon. hoofdstuk :49 Pagina 89
hoofdstuk 06 19-12-2001 09:49 Pagina 89 Urethral Resistance Factor (URA) Versus Schäfer s Obstruction Grade and Abrams-Griffiths (AG) Number in the Diagnosis of Obstructive Benign Prostatic Hyperplasia
More informationWhat can the primary care physician do? Brian W. Ellis
What can the primary care physician do? Brian W. Ellis Consultant Urological Surgeon at Ashford & St Peter s 1983-2007 Currently Consultant Urological Surgeon at Cobham Hospital Visiting Professor at Middlesex
More informationChapter 3: Results of the Treatment Outcomes Analyses
Chapter 3: Results of the Treatment Outcomes Analyses Introduction To determine the appropriateness of individual therapies, as well as to develop practice recommendations, the American Urological Association
More informationThe potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians
Therapeutic Advances in Chronic Disease Review The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians Neal Shore and Barrett Cowan Ther Adv Chronic Dis (2011) 2(6) 377 383
More informationCase studies: LUTS. Case 1 history. Case 1 - questions. Case 1 - outcome. Case 2 - history. Case 1 learning point 14/07/2015 DR JON REES
Case 1 history Case studies: LUTS DR JON REES A 49 year old male comes to see you he has had gradual deterioration of his flow over the last few years- he saw a colleague of yours 6 weeks ago who recorded
More informationThe Journal of International Medical Research 2005; 33:
The Journal of International Medical Research 2005; 33: 562 573 A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia:
More informationRELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
American Urological Association symptom index for BPH RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTION IN PATIENTS WITH
More informationThe population of subjects which was statistically analyzed was the Intent-to-Treat population
Study No.: ARIB3003 (Year 1) Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression
More informationPolicy for Prostatism/Lower Urinary Tract Symptoms in men
NHS Halton Clinical Commissioning Group NHS Liverpool Clinical Commissioning Group NHS St Helens Clinical Commissioning Group NHS South Sefton Clinical Commissioning Group NHS Southport and Formby Clinical
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: None Prostatic Urethral Lift Description Benign prostatic hyperplasia (BPH) is a common condition in older individuals that can
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationVoiding Dysfunction Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU.
Voiding Dysfunction 2009 Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU. Objectives Understand and explain physiologic function and dysfunction of lower urinary tract.
More informationA Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia
Chattagram Maa-O-Shishu Hospital Medical College Journal Original Article A Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia
More informationDepartment of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX
NEW PERSPECTIVES ON BPH 5- -Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia Claus G. Roehrborn, MD Department of Urology, The University of Texas Southwestern Medical Center
More informationKorean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic Hyperplasia: A Nationwide Survey
Original Article DOI 10.3349/ymj.2010.51.2.248 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 51(2):248-252, 2010 Korean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic
More informationREVIEW The role of combination medical therapy in benign prostatic hyperplasia
(2008) 20, S33 S43 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir REVIEW The role of combination medical therapy in benign prostatic hyperplasia Department of
More informationBPH / LUTS. Prevalence. Prevalence of BPH. It is abnormal NOT to have benign growth of the prostate with increasing age. Prevalence.
BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG FECSM Beaconsfield Medical Practice, Brighton & Brighton & Sussex Universities NHS Trust As man draws near the common goal Can anything be sadder Than he
More informationPATIENT INFORMATION 2017 NeoTract, Inc. All rights reserved. Printed in the USA. MAC Rev A
PATIENT INFORMATION OVER 70% OF MEN IN THEIR 60s HAVE SYMPTOMS OF BPH 1 BPH affects more than 500 million men worldwide, with many men suffering from symptoms of enlarged prostate. 1 You no longer have
More informationEuropean Healthcare Innovation Leadership Network
MAY 2008 The Value Proposition of Medicines to Treat Benign Prostatic Hyperplasia: Introduction The following case study examines the evolution of Avodart, a drug manufactured by GSK that is currently
More informationPROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA
St. Louis Hospital PROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA INITIAL CLINICAL RESULTS Faculty of Medical Sciences New University of Lisbon JOÃO PISCO LUÍS CAMPOS PINHEIRO TIAGO BILHIM HUGO RIO TINTO
More informationA Study of Relationship of Prostate Volume, Prostate Specific Antigen and age in Benign Prostatic Hyperplasia
ORIGINAL RESEARCH www.ijcmr.com A Study of Relationship of Prostate Volume, Prostate Specific Antigen and age in Benign Prostatic Hyperplasia Rupam Deori 1, Bijoyananda Das 2, Mustafa Abdur Rahman 3 ABSTRACT
More informationBenign Prostatic Hyperplasia. Shahideh Amini Pharm.D clinical pharmacy resident Tehran university of medical science Department of pharmacotherapy
Benign Prostatic Hyperplasia Shahideh Amini Pharm.D clinical pharmacy resident Tehran university of medical science Department of pharmacotherapy Definition BPH is a common disorder that increases in frequency
More informationEvidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care
REVIEW C URRENT OPINION Evidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care Seth A. Strope Purpose of review Guidelines have been developed
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: January 15, 2019 Related Policies: None Prostatic Urethral Lift Description Benign prostatic hyperplasia (BPH) is a common condition in older individuals that
More informationLower Urinary Tract Symptoms
Advances in the management of BPH/LUTS Greetings from the Executive and Members of the European Association of Urology Christopher Chapple Professor of Urology Sheffield Hallam University Consultant Urological
More informationAUCKLAND REGIONAL UROLOGY GUIDELINES AND REFERRAL RECOMMENDATIONS
AUCKLAND REGIONAL UROLOGY GUIDELINES AND REFERRAL RECOMMENDATIONS This document outlines the urological conditions currently funded at Auckland District Health Board (ADHB), Counties Manukau District Health
More informationManagement of male LUTS in general practice
17 Management of male LUTS in general practice MARK J. SPEAKMAN AND FAITH MCMEEKIN The initial management of lower urinary tract symptoms in men is usually carried out in primary care. The authors explain
More information10/9/2015. Dana A. Brown, Pharm.D., BCPS Assistant Dean for Academics, Associate Professor of Pharmacy Practice Palm Beach Atlantic University
Dana A. Brown, Pharm.D., BCPS Assistant Dean for Academics, Associate Professor of Pharmacy Practice Palm Beach Atlantic University 1. Explain the pathophysiology of benign prostatic hyperplasia (BPH),
More informationThe good news is that beta-sitosterol costs so little that men can increase their consumption without spending extra dollars.
Life Extension http://www.lifeextension.com Life Extension Magazine June 2005 Report Beta-Sitosterol By Stephen B. Strum, MD, FACP, and William Faloon Whether from benign enlargement or cancer, prostate
More informationTreating BPH: Comparing Rezum UroLift and HoLEP
Treating BPH: Comparing Rezum UroLift and HoLEP Scott M. Cheney MD Mayo Clinic Arizona 2018 MFMER slide-1 Welcome to AZ 2018 MFMER slide-2 Outline Background on BPH, Rezum, Urolift, HoLEP AUA Guideline
More informationOriginal Policy Date
MP 7.01.39 Transurethral Microwave Thermotherapy Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical
More informationProstate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต
Prostate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต Prostate cancer Overview Diagnosis Treatment Lower urinary tract symptoms EPIDEMIOLOGY The most common
More information